ReviewDer Radiologe2017
[Tumors of the sellar region].
Review in Der Radiologe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Endoscopic endonasal resection of neurohypophyseal granular cell tumor: a case report and review of 88 published cases.Frontiers in endocrinology · 2026Review
- Case report: Clinical report of co-occurrence of pituitary adenoma and meningioma in the sellar region after meningioma treatment.Frontiers in neurology · 2022Article
- Pharmacokinetic analysis for the differentiation of pituitary microadenoma subtypes through dynamic contrast-enhanced magnetic resonance imaging.Oncology letters · 2019Article
- [Intracranial cystic lesions].Der Radiologe · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodical issueThe anatomy of the sellar region is complex and tumors of the sellar region are very variable because they arise from the many different tissue types in the sellar region, ranging from benign to life-threatening. Despite this variety, approximately 80% of sellar region tumors are due to the 5 most common lesions: adenomas, meningiomas, aneurysms, astrocytomas and craniopharyngiomas. STANDARD RADIOLOGICAL
methodsIn addition to clinical and laboratory results, the magnetic resonance imaging (MRI) and computed tomography (CT) results including the exact anatomical position and the proliferation pattern of the lesion are decisive for the diagnosis. The gold standard for diagnostic imaging is multiplanar, thin section, contrast-enhanced MRI with soft tissue contrast. Vessel imaging and CT are complementary modalities in selected cases and often for preoperative planning. METHODICAL INNOVATIONS: Whereas most sellar region tumors can be well visualized with multiplanar, contrast-enhanced MRI, for very small intrapituitary microadenomas dynamic contrast-enhanced T1-weighted sequences can be necessary. Microadenomas can often only be clearly demarcated from the rest of the pituitary tissue due to the different perfusion pattern. Optimized diffusion-weighted images can also be useful for narrowing down the differential diagnoses of sellar region tumors. PERFORMANCE AND ACHIEVEMENTS: Tumors of the sellar region can be subdivided in intrahypophysial and extrahypophysial lesions as well as intrinsic skull base lesions. The most common sellar tumors are adenomas of the pituitary gland, which can be subdivided into microadenoma and macroadenoma and into secretory and non-secretory. PRACTICAL RECOMMENDATIONS: If there is suspicion of a sellar region lesion due to clinical or laboratory results, multiplanar contrast enhanced thin section MRI of the sellar region should be used as the primary imaging modality. The keys to the diagnosis are the precise anatomical location of the lesion and the proliferation pattern. The most common lesions in the sellar region are pituitary gland adenomas, which can be small and often secretory or larger and often non-secretory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.